CSPC Innovation Pharmaceutical Co Ltd banner
C

CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765

Watchlist Manager
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Watchlist
Price: 32.87 CNY -3.32% Market Closed
Market Cap: ¥46.2B

CSPC Innovation Pharmaceutical Co Ltd
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

CSPC Innovation Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Total Current Liabilities
¥2.7B
CAGR 3-Years
67%
CAGR 5-Years
63%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Liabilities
¥4.4B
CAGR 3-Years
19%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Liabilities
¥6.4B
CAGR 3-Years
21%
CAGR 5-Years
11%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Liabilities
¥12.9B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
11%
Zhejiang Nhu Co Ltd
SZSE:002001
Total Current Liabilities
¥7.4B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
12%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Liabilities
¥2B
CAGR 3-Years
61%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

CSPC Innovation Pharmaceutical Co Ltd
Glance View

Market Cap
46.2B CNY
Industry
Pharmaceuticals

Nestled in the dynamic landscape of the pharmaceutical industry, CSPC Innovation Pharmaceutical Co Ltd stands as a beacon of innovation and ambition. Evolving from its roots in traditional pharmaceutical practices, the company has carved out a niche for itself by embracing cutting-edge research and development methodologies. At the core of their operations is an unwavering commitment to creating novel drugs that target complex medical challenges. This commitment is propelled by their significant investment in state-of-the-art R&D facilities and collaborations with leading academic institutions and biotech firms. By fostering a rich pipeline of new drugs, CSPC Innovation strives to maintain its competitive edge in a rapidly changing market, driven by both pressing healthcare needs and technological advancements. The company leverages its robust distribution network to bring these innovations to market, drawing upon a diverse portfolio that includes drugs for therapeutic areas such as oncology, cardiovascular health, and metabolic disorders. Revenue generation, therefore, hinges largely on the successful commercialization of these pharmaceutical products, through both direct sales and strategic partnerships. Additionally, CSPC Innovation engages in manufacturing and selling Active Pharmaceutical Ingredients (APIs), further diversifying its income streams. By balancing risk and opportunity, the company not only aims to meet the immediate health demands of its consumer base but also positions itself to capture long-term growth within the global healthcare sector, ensuring a steady influx of revenue and sustainability for future endeavors.

Intrinsic Value
9.44 CNY
Overvaluation 71%
Intrinsic Value
Price ¥32.87
C

See Also

What is CSPC Innovation Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
2.7B CNY

Based on the financial report for Dec 31, 2025, CSPC Innovation Pharmaceutical Co Ltd's Total Current Liabilities amounts to 2.7B CNY.

What is CSPC Innovation Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
63%

Over the last year, the Total Current Liabilities growth was 89%. The average annual Total Current Liabilities growth rates for CSPC Innovation Pharmaceutical Co Ltd have been 67% over the past three years , 63% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett